Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.
- Post-trial access enables ongoing DMX-200 treatment for eligible FSGS patients
- Access pathways vary by jurisdiction, including expanded and compassionate use
- Commercial partners manage access in licensed territories; Dimerix covers unlicensed regions
- DMX-200 remains investigational; data collection during post-trial access limited to safety
- Supports patient continuity of care amid limited approved therapies for FSGS
Post-Trial Access Program Launched for DMX-200
Dimerix Limited (ASX:DXB) has announced that patients who completed the pivotal ACTION3 Phase 3 trial and its Open Label Extension (OLE) study will be able to continue receiving DMX-200 through post-trial access pathways. This move aims to maintain treatment continuity for eligible patients with focal segmental glomerular sclerosis (FSGS), a rare and serious kidney disease with few approved therapies.
The post-trial access program is designed to provide ongoing use of DMX-200 under physician supervision for patients who have no suitable alternative treatments and who have completed the clinical trial protocol. Access will be governed by local regulatory frameworks and may take the form of expanded access, compassionate use, special access, or equivalent pathways depending on jurisdiction. Importantly, this access does not constitute regulatory approval, and DMX-200 remains an investigational drug during this period.
Commercial Partners to Manage Access by Territory
Dimerix’s commercial partners will handle post-trial access arrangements, including supply costs, within their licensed territories. For regions where no commercial partner has been appointed, Dimerix will assume responsibility. This division of duties reflects a coordinated approach to patient care and commercial strategy ahead of regulatory milestones.
The company emphasises that data collection from patients accessing DMX-200 post-trial will be primarily limited to safety monitoring. This approach balances patient access with ongoing pharmacovigilance while awaiting formal regulatory decisions.
Background on the ACTION3 Phase 3 Trial
The ACTION3 study is a multi-centre, randomised, double-blind, placebo-controlled Phase 3 trial evaluating DMX-200's efficacy and safety in FSGS patients who are stable on angiotensin II receptor blockers (ARBs). The trial’s primary endpoint is the percent change in proteinuria, a key marker of kidney damage, with secondary measures including kidney function decline (eGFR slope). The trial enrolled over 300 adult patients across 21 countries and is expected to deliver final data by 2028 to support regulatory submissions.
DMX-200 is a chemokine receptor CCR2 antagonist designed to complement standard care ARBs by targeting inflammatory pathways implicated in FSGS progression. It holds orphan drug designations in the US, Europe, UK, and Japan, with patent protection potentially extending to 2042. Despite promising clinical development, DMX-200 has not yet received marketing approval.
Addressing an Unmet Medical Need
FSGS is characterised by progressive scarring of kidney filtering units, leading to proteinuria and eventual kidney failure. With no approved therapies specifically for FSGS in the US and limited options globally, disease management relies on immunosuppressants and supportive care. The average time to end-stage kidney disease can be as short as five years, and recurrence after transplantation is common.
Dimerix’s post-trial access initiative underscores its commitment to patient continuity of care and addressing this significant unmet need. By enabling access to DMX-200 prior to regulatory approval, the company and its partners aim to support patients who may benefit from ongoing treatment.
Bottom Line?
Dimerix’s post-trial access program for DMX-200 offers a vital bridge for FSGS patients pending regulatory approval, but the therapy remains investigational with safety data collection ongoing.
Questions in the middle?
- Which jurisdictions will implement post-trial access first, and under what regulatory frameworks?
- How will Dimerix and its partners balance expanded access with commercial launch preparations?
- What safety signals, if any, emerge from patients receiving DMX-200 through post-trial pathways?